ArticleACS medicinal chemistry letters2019
Evolution of Small Molecule Kinase Drugs.
Article in ACS medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Precision Covalent Drug Discovery Inspired by Endogenous Electrophilic Signalling in Immune Cells.Biomedicines · 2026Article
- Occurrence of "Natural Selection" in Successful Small Molecule Drug Discovery.Journal of medicinal chemistry · 2024Article
- Small molecule inhibitors target multiple neuropathological signaling to exert novel neuroprotection in intracranial aneurysms.Frontiers in pharmacology · 2024Review
- An essentialFrontiers in parasitology · 2023Article
- GCN2 kinase activation by ATP-competitive kinase inhibitors.Nature chemical biology · 2022Article
- Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds.ACS medicinal chemistry letters · 2021Article
- 7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-ones Designed by a "Cut and Glue" Strategy Are Dual Aurora A/VEGF-R Kinase Inhibitors.Molecules (Basel, Switzerland) · 2021Article
- Identification of Potent Reverse Indazole Inhibitors for HPK1.ACS medicinal chemistry letters · 2021Article
- Structural Basis for Targeting the Folded P-Loop Conformation of c-MET.ACS medicinal chemistry letters · 2021Article
- Activity-Based Kinome Profiling Using Chemical Proteomics and ATP Acyl Phosphates.Current protocols in chemical biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of small molecule kinase drugs is a rapidly evolving field and represents one of the most important research areas within oncology. This innovation letter provides an overview and analysis of approved kinase drugs according to their WHO registration (INN) dates, primary biological targets, and selectivity and structural similarities, which are also depicted in an associated poster. It also discusses new trends in kinase drug discovery programs such as new kinase targets, novel mechanisms of action, and diverse indications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.